The IMmunotherapy Pleural 5-ALA PDT

Overview

Pilot study of the feasibility of an innovative multimodal treatment combining intrapleural photodynamic therapy with videothoracoscopy followed by adjuvant immunotherapy with anti-PD-1 Nivolumab antibodies in patients with malignant pleural mesothelioma

Full Title of Study: “Intrapleural Photodynamic Therapy by Video-Assisted Thoracoscopy Followed by Anti-PD-1 NIVOLUMAB in Patients With Malignant Pleural Mesothelioma – a Pilot Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2024

Interventions

  • Device: intrapleural photodynamic therapy with videothoracoscopy
    • MPM patients will be first administrated 20 mg/kg of oral photosensitizer, 5-Aminolevulinic Acid (5-ALA) {Gliolan®}, 4 to 6 hours prior undergoing thoracoscopy (VATS). During VATS procedure, after a qualitative control of the fluorescence of tumor lesions and some guided pleural tumor biopsies, the pleural cavity will be illuminated using a flexible probe and laser source at a specific wavelength for 5-ALA (400-500 nm; 25 J/cm2) during 15 minutes (6 fractions of 2.5 minutes separated by 5 pauses of 2 minutes each to improve tissue oxygenation for the PDT reaction). An IPC device (but no talc) will be inserted and used for pleurodesis and may permit to collect further pleural effusion samples. As 5-ALA has a short half-life and thus does not need extensive precautions to avoid patient photosensitivity, the patient would not stay longer than a standard procedure (about 2-3 days in the hospital)
  • Drug: Nivolumab Injection
    • Seven to 10 days after VATS, patients will start to be treated by Nivolumab 240mg IV every 2 weeks till progression (CT-scan reassessment every 8 cycles), unacceptable toxicity, or maximum 2 years.

Arms, Groups and Cohorts

  • Experimental: Malignant Pleural Mesothelioma patients

Clinical Trial Outcome Measures

Primary Measures

  • the proportion of patients having the full multimodal treatment
    • Time Frame: through study completion, an average of 24 months
    • the proportion of patients having the full multimodal treatment (target: 70% minimum of total patients,14 out of 20 patients) without inacceptable and unexpected toxicity (grade≥3) according National Cancer Institute (NCI) criteria, reviewed by an Independent Survey Committee.

Secondary Measures

  • objective response rate (ORR) according to modified RECIST 1.1 criteria for mesothelioma for pleural lesions; RECIST 1.1 for all other targets
    • Time Frame: through study completion, an average of 24 months
  • Kaplan Meier curve for overall survival (mOS)
    • Time Frame: through study completion, an average of 24 months
  • Kaplan Meier curve for progression free survival (mPFS)
    • Time Frame: through study completion, an average of 24 months
  • quality of life (QoL) of patients by dedicated EORTC QLQ C30 (or LCSS-30) questionnaire
    • Time Frame: At baseline and
    • The Quality of life questionnaire (QLQ-C30) contains 29 items dealing with fatigue, pain, nausea and vomiting, general condition and social, emotional and cognitive functions. It is currently used in many clinical trials in oncology
  • evaluation of chest pain using visual scale.
    • Time Frame: through study completion, an average of 24 months

Participating in This Clinical Trial

Inclusion Criteria

  • ECOG Performance status (PS) 0-1 (WHO)
  • Unresectable Malignant Pleural Mesothelioma
  • suffering from unresectable MPM (n=20), relapsing after one or 2 lines of treatment with platinum-based doublet of chemotherapy (including pemetrexed) [Note: MPM patients having contra-indications for, or refusing chemotherapy may also be recruited], and candidate for palliative pleural procedure (i.e. thoracoscopy for pleurodesis by talc or by insertion of indwelled pleural catheter, IPC)
  • Documented progression after previous 1 or 2 lines of chemotherapy including Platinum/Pemetrexed chemotherapy*
  • Measurable disease according to modified RECIST 1.1. for MPM
  • Malignant pleural lesion assessed to be accessible by local PDT treatment during thoracoscopy, as validated by expert MTB ("MESOCLIN", Lille, France)
  • Histological diagnosis confirmed by national expert pathology panel ("MESOPATH" Institut Léon Bérard, Lyon, France)
  • Weight loss <10%
  • available tumor tissue (archival or fresh)
  • obtention of an informed written consent before any specific procedure of the study
  • Decision to treat the patient within this clinical trial taken during MPM dedicated multidisciplinary board (RCP MESOCLIN in France )
  • Patient affiliated to and covered by social security for standard care
  • Women of child-bearing potential must use a highly effective method of contraception for 28 days prior to the first dose of investigational product, and must agree to continue using such precautions for 5 months after the final dose of investigational product
  • Women of child-bearing potential must have a negative pregnancy test within 24h before administration of investigational product
  • First line patients may also be recruited if they declined or if they have contra-indications for chemotherapy.

Exclusion Criteria

  • lack of informed written consent; or refusal to sign or to participate
  • Pregnant, breastfeeding patients, and female patients of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in the protocol for the duration of the study and for at least 5 months after the last dose of nivolumab
  • Male patients who are unwilling or unable to use contraception methods for the duration of the study and for at least 7 months after the last dose of nivolumab
  • a previous treatment by anti-PD-1 or anti-PD-L1 antibodies for their cancer or any other cancer in the last 5 years
  • hypersensitivity to Nivolumab (anti-PD-1 antibodies)
  • contra-indications for 5-ALA or PDT
  • contra-indications for thoracoscopy (VATS)
  • any other comorbidity precluding the feasibility of the therapeutic protocol: uncontrolled cardiac failure, pulmonary hypertension, liver or kidney severe dysfunction (creatinin clearance <60 ml/min), uncontrolled infection, or other disease according to the investigator
  • other cancer treated within 5 years before inclusion except baso-cellular skin carcinoma or cervical / bladder in situ carcinoma
  • inability to receive study information and to give informed consent
  • patient unable to have a clinical follow-up due to psychological, familial, social or geographical reasons
  • legal incapacity (people in jail), or under supervision (i.e. guardianship or curatorship)
  • treatment with experimental drug within 30 days before the start of the study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Lille
  • Collaborator
    • Bristol-Myers Squibb
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Arnaud Scherpereel, MD,PhD, Principal Investigator, University Hospital, Lille
  • Overall Contact(s)
    • Arnaud Scherpereel, MD,PhD, 320444998, arnaud.scherpereel@chru-lille.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.